Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial.
- DOI
- 10.1016/s0140-6736(26)00748-8
- Published
- 2026 Jun 20
- Container
- Lancet (London, England)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s0140-6736-26-00748-8,
title = {Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial.},
author = {Davies MJ and Aroda VR and Rosenstock J and Capehorn M and Pedersen SD and Morizzo E and Malhotra S and Johansson PA and Grice D and Andersson A and Rizi EP and Sjöström CD},
year = {2026},
journal = {Lancet (London, England)},
doi = {10.1016/s0140-6736(26)00748-8},
url = {https://doi.org/10.1016/s0140-6736(26)00748-8}
}RIS
TY - JOUR TI - Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial. AU - Davies MJ AU - Aroda VR AU - Rosenstock J AU - Capehorn M AU - Pedersen SD AU - Morizzo E AU - Malhotra S AU - Johansson PA AU - Grice D AU - Andersson A AU - Rizi EP AU - Sjöström CD PY - 2026 JO - Lancet (London, England) DO - 10.1016/s0140-6736(26)00748-8 UR - https://doi.org/10.1016/s0140-6736(26)00748-8 ER -
APA
MJ, D., VR, A., J, R., M, C., SD, P., E, M., S, M., PA, J., D, G., A, A., EP, R., & CD, S. (2026). Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)00748-8
Source records
- pubmed · retrieved 2026-09-25T12:38:05.982Z